Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Egle

Showing results (1-10 of 37) with videos related to

Pageof 4
Sort By:
Deutsche Medizinische Wochenschrift (1946)|October 3, 2013
[Autoimmune hemolysis accompanied by thrombopenia: consumption or myelodysplasia?]T Melchardt, L Weiss, A Egle
Leukemia & Lymphoma|January 28, 1999
On the role and significance of Fas (Apo-1/CD95) ligand (FasL) expression in immune privileged tissues and cancer cells using multiple myeloma as a modelR Greil, A Egle, A Villunger
Current Biology : CB|December 19, 2001
TNF cytokine family: more BAFF-ling complexitiesY Laâbi, A Egle, A Strasser
ESMO Open|January 12, 2023
How I treat diffuse large B-cell lymphomaT Melchardt, A Egle, R Greil
International Journal of Cancer|April 1, 1991
B-859-35, a new drug with anti-tumor activity reverses multi-drug resistanceJ Hofmann, F Ueberall, A Egle, et al.
Oncogene|July 31, 2009
Bim and Bmf in tissue homeostasis and malignant diseaseJ D Piñon, V Labi, A Egle, et al.
Cell Death and Differentiation|June 11, 2013
Bid-ding for mercy: twisted killer in actionA Egle, D Asslaber, A Villunger, et al.
Blood|January 11, 2000
Expression of functional interleukin-15 receptor and autocrine production of interleukin-15 as mechanisms of tumor propagation in multiple myelomaI Tinhofer, I Marschitz, T Henn, et al.
British Journal of Haematology|July 1, 1996
IL-10 serum levels in B-cell chronic lymphocytic leukaemiaA Egle, I Marschitz, B Posch, et al.
International Journal of Cancer|February 8, 1996
Constituents of autocrine IL-6 loops in myeloma cell lines and their targeting for suppression of neoplastic growth by antibody strategiesA Villunger, A Egle, M Kos, et al.
Pageof 4

Showing results (1-10 of 37) with videos related to

Sort By:
Pageof 4
Deutsche Medizinische Wochenschrift (1946)|October 3, 2013
[Autoimmune hemolysis accompanied by thrombopenia: consumption or myelodysplasia?]T Melchardt, L Weiss, A Egle
Leukemia & Lymphoma|January 28, 1999
On the role and significance of Fas (Apo-1/CD95) ligand (FasL) expression in immune privileged tissues and cancer cells using multiple myeloma as a modelR Greil, A Egle, A Villunger
Current Biology : CB|December 19, 2001
TNF cytokine family: more BAFF-ling complexitiesY Laâbi, A Egle, A Strasser
ESMO Open|January 12, 2023
How I treat diffuse large B-cell lymphomaT Melchardt, A Egle, R Greil
International Journal of Cancer|April 1, 1991
B-859-35, a new drug with anti-tumor activity reverses multi-drug resistanceJ Hofmann, F Ueberall, A Egle, et al.
Oncogene|July 31, 2009
Bim and Bmf in tissue homeostasis and malignant diseaseJ D Piñon, V Labi, A Egle, et al.
Cell Death and Differentiation|June 11, 2013
Bid-ding for mercy: twisted killer in actionA Egle, D Asslaber, A Villunger, et al.
Blood|January 11, 2000
Expression of functional interleukin-15 receptor and autocrine production of interleukin-15 as mechanisms of tumor propagation in multiple myelomaI Tinhofer, I Marschitz, T Henn, et al.
British Journal of Haematology|July 1, 1996
IL-10 serum levels in B-cell chronic lymphocytic leukaemiaA Egle, I Marschitz, B Posch, et al.
International Journal of Cancer|February 8, 1996
Constituents of autocrine IL-6 loops in myeloma cell lines and their targeting for suppression of neoplastic growth by antibody strategiesA Villunger, A Egle, M Kos, et al.
Pageof 4